Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
In Guru Portfolios
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
InnovAge Holding Corp. specializes in providing a comprehensive suite of medical and supportive services designed to empower older adults to maintain independence within their homes and communities. Its operational framework is based on the Program of All-Inclusive Care for the Elderly (PACE) model. The company's diverse service offerings encompass both in-home assistance (including skilled, unskilled, and personal care) and on-site center-based provisions. These center services span primary medical care, various therapies (physical, occupational, speech), dental services, mental health support, nutritious meals, and engaging activities. Additionally, InnovAge facilitates transportation to PACE centers and external medical appointments, alongside comprehensive care management. The company currently supports approximately 6,850 PACE participants across the United States, operating 18 dedicated PACE centers in key states including Colorado, California, New Mexico, Pennsylvania, and Virginia. Established in 2007, the company was formerly known as TCO Group Holdings, Inc. before rebranding as InnovAge Holding Corp. in January 2021. InnovAge maintains its corporate headquarters in Denver, Colorado.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/F
Target Price
The average target price of INNV is 7.0 and suggests 25% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr